ArticleOrphanet journal of rare diseases2021
Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment.
Article in Orphanet journal of rare diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The use of digital outcome measures in clinical trials in rare neurological diseases: a systematic literature review.Orphanet journal of rare diseases · 2023Pooled it
- Article
- Stride-level measurement of gait as an early sensitive marker of disability progression in ambulatory patients with multiple sclerosis.EClinicalMedicine · 2026Article
- Real-world walking speed as a digital biomarker and outcome measure for clinical trials-a systematic review, regulatory status and future directions.Frontiers in digital health · 2026Review
- Digital outcome measures in Duchenne muscular dystrophy: Lessons learnt from clinical trials.Journal of neuromuscular diseases · 2026Review
- Gait speed as a superior screening indicator for mild cognitive impairment compared to walk ratio and dual-task cost: a cross-sectional study.European geriatric medicine · 2025Article
- Harnessing Fast Fourier Transform for Rapid Community Travel Distance and Step Estimation in Children with Duchenne Muscular Dystrophy.Sensors (Basel, Switzerland) · 2025Article
- Feasibility and usability of a wearable sensor system for gait assessment in children with neuromuscular diseases.Frontiers in rehabilitation sciences · 2025Article
- Article
- Evidentiary basis of the first regulatory qualification of a digital primary efficacy endpoint.Scientific reports · 2024Article
- Gait Variability as a Potential Motor Marker of Cerebellar Disease-Relationship between Variability of Stride, Arm Swing and Trunk Movements, and Walking Speed.Sensors (Basel, Switzerland) · 2024Article
- The Analytical Validity of Stride Detection and Gait Parameters Reconstruction Using the Ankle-Mounted Inertial Measurement Unit SydeSensors (Basel, Switzerland) · 2024Article
- Ten meter walk test with mobile devices: A dataset with accelerometer, magnetometer, and gyroscope.Data in brief · 2024Article
- Stride Velocity 95th Centile Detects Decline in Ambulatory Function Over Shorter Intervals than the 6-Minute Walk Test or North Star Ambulatory Assessment in Duchenne Muscular Dystrophy.Journal of neuromuscular diseases · 2024Article
- Mobile and wearable technologies for the analysis of Ten Meter Walk Test: A concise systematic review.Heliyon · 2023Article
- Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials.Journal of neuromuscular diseases · 2022Article
- Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundNormative data are necessary for validation of new outcome measures. Recently, the 95th centile of stride speed was qualified by the European Medicines Agency as a valid secondary outcome for clinical trials in subjects with Duchenne muscular dystrophy. This study aims to obtain normative data on spontaneous stride velocity and length in a non-controlled environment and their evolution after 12 months.
methodNinety-one healthy volunteers (50 females, 41 males), with a mean age of 16 years and 2 months, were recruited and assessed at baseline and 12 months later. The 4-stair climb, 6-min walk test, 10-m walk test and rise from floor assessments were performed. Stride length, stride velocity, and the distance walked per hour were studied in an everyday setting for one month after each evaluation.
resultsOf the 91 subjects assessed, 82 provided more than 50 h of recordings at baseline; and 73 subjects provided the same at the end of the year. We observed significant positive correlations of the stride length with age and height of participants, and a significant increase of the median stride length in children after the period. In this group, the 95th centile stride velocity was not correlated with age and was stable after one year. All measures but the 10MWT were stable in adults after a one-year period.
conclusionThis study provides with data on the influence of age, height, and gender on stride velocity and length as well as accounting for natural changes after one year in controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.